[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11202108707WA - Methods and agents for assessing t-cell function and predicting response to therapy - Google Patents

Methods and agents for assessing t-cell function and predicting response to therapy

Info

Publication number
SG11202108707WA
SG11202108707WA SG11202108707WA SG11202108707WA SG11202108707WA SG 11202108707W A SG11202108707W A SG 11202108707WA SG 11202108707W A SG11202108707W A SG 11202108707WA SG 11202108707W A SG11202108707W A SG 11202108707WA SG 11202108707W A SG11202108707W A SG 11202108707WA
Authority
SG
Singapore
Prior art keywords
assessing
therapy
agents
methods
cell function
Prior art date
Application number
SG11202108707WA
Inventor
Sudha Rao
Robert Mccuaig
Original Assignee
Epiaxis Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019900628A external-priority patent/AU2019900628A0/en
Application filed by Epiaxis Therapeutics Pty Ltd filed Critical Epiaxis Therapeutics Pty Ltd
Publication of SG11202108707WA publication Critical patent/SG11202108707WA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/10—Post-translational modifications [PTMs] in chemical analysis of biological material acylation, e.g. acetylation, formylation, lipoylation, myristoylation, palmitoylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/12—Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202108707WA 2019-02-27 2020-02-27 Methods and agents for assessing t-cell function and predicting response to therapy SG11202108707WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2019900628A AU2019900628A0 (en) 2019-02-27 Methods and agents for assessing t-cell function and predicting response to therapy
PCT/AU2020/050172 WO2020172712A1 (en) 2019-02-27 2020-02-27 Methods and agents for assessing t-cell function and predicting response to therapy

Publications (1)

Publication Number Publication Date
SG11202108707WA true SG11202108707WA (en) 2021-09-29

Family

ID=72238249

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108707WA SG11202108707WA (en) 2019-02-27 2020-02-27 Methods and agents for assessing t-cell function and predicting response to therapy

Country Status (8)

Country Link
US (1) US20220146495A1 (en)
EP (1) EP3931565A4 (en)
JP (1) JP7520389B2 (en)
CN (1) CN113677994A (en)
AU (1) AU2020227319A1 (en)
CA (1) CA3131268A1 (en)
SG (1) SG11202108707WA (en)
WO (1) WO2020172712A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240301019A1 (en) * 2021-02-15 2024-09-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Recombinant eomes restores anti-cancer activity of immune cells
KR102534243B1 (en) * 2022-12-05 2023-05-31 넥스탭 주식회사 Method of identifying IFN-γ regulating agent targeting Eomes protein and medicament comprising the agent

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
ATE135373T1 (en) 1989-09-08 1996-03-15 Univ Johns Hopkins MODIFICATIONS OF THE STRUCTURE OF THE EGF RECEPTOR GENE IN HUMAN GLIOMA
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ES2166368T3 (en) 1993-12-24 2002-04-16 Merck Patent Gmbh IMMUNOCONJUGADOS.
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
DK0817775T3 (en) 1995-03-30 2001-11-19 Pfizer quinazoline
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
EA001428B1 (en) 1995-07-06 2001-02-26 Новартис Аг Pyrrolopyrimidines and pharmaceutical compositions
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
BR9708640B1 (en) 1996-04-12 2013-06-11 irreversible tyrosine kinase inhibitors and pharmaceutical composition comprising them.
DE69716916T2 (en) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
ID18494A (en) 1996-10-02 1998-04-16 Novartis Ag PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT
UA73073C2 (en) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CN1195521C (en) 1997-05-06 2005-04-06 惠氏控股公司 Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
WO1999024037A1 (en) 1997-11-06 1999-05-20 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
GEP20032997B (en) 1998-11-19 2003-06-25 Warner Lambert Co N-[4-(3-Chloro-4-Fluoro-Phenylamino)-7-(3-Morpholin-4-Yl-Propoxy)-Quinazolin-6-Yl]-crylamide, as an Irreversible Inhibitor of Tyrosine Kinases
EP1236173A2 (en) 1999-10-27 2002-09-04 Biowulf Technologies, LLC Methods and devices for identifying patterns in biological systems
EP1386275A2 (en) 2000-07-18 2004-02-04 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
ATE540421T1 (en) 2000-11-16 2012-01-15 Bio Rad Laboratories METHOD FOR ANALYZING MASS SPECTRA
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
JP2011160711A (en) * 2010-02-09 2011-08-25 Keio Gijuku Method for using frequency of methylation of specific gene as biomarker for gynecologic cancer
GB201316347D0 (en) 2013-09-13 2013-10-30 Cancer Rec Tech Ltd Biological fluid filtration assembly
AU2015331923B2 (en) * 2014-10-17 2020-12-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators
EP3277689B1 (en) * 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
CN106047818A (en) * 2016-08-05 2016-10-26 武汉赛云博生物科技有限公司 Oncofetal antigen-specific TCR gene-modified T cell and cancer inhibition use thereof
US20200054660A1 (en) 2016-12-09 2020-02-20 St. Jude Children's Research Hospital Dna methylation profiling for t-cell immunotherapy

Also Published As

Publication number Publication date
EP3931565A4 (en) 2023-04-12
CA3131268A1 (en) 2020-09-03
JP2022522185A (en) 2022-04-14
JP7520389B2 (en) 2024-07-23
US20220146495A1 (en) 2022-05-12
AU2020227319A1 (en) 2021-09-09
WO2020172712A1 (en) 2020-09-03
CN113677994A (en) 2021-11-19
EP3931565A1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
IL266382A (en) Methods for assessing risk using total and specific cell-free dna
SG11202102255VA (en) Methods and systems for therapeutic agent analysis
WO2016073380A8 (en) Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
IL276813A (en) Arginase inhibitors
IL290908A (en) Platform for discovery and analysis of therapeutic agents
EP4048809A4 (en) Systems and methods for predicting therapeutic sensitivity
EP3519828A4 (en) Methods and apparatus for assessing immune system activity and therapeutic efficacy
SG11202006441SA (en) Agents and methods for predicting response to therapy
IL273252A (en) Compositions and methods for predicting response to napi2b-targeted therapy
IL268209A (en) Methods for identifying and using small rna predictors
HUE056501T2 (en) Isoform selective tgfbeta1 inhibitors and use thereof
PH12017502099A1 (en) Methods for diagnosing and assessing treatment for cushing's syndrome
IL283165A (en) Adenoviruses and methods for using adenoviruses
SG11202108707WA (en) Methods and agents for assessing t-cell function and predicting response to therapy
SG11202110011WA (en) Analysis systems and methods
GB2588272B (en) Portable brain function monitor
SG11202004812VA (en) A dual-column lc-ms system and methods of use thereof
AU2019900628A0 (en) Methods and agents for assessing t-cell function and predicting response to therapy
GB2595605B (en) Genotype analysis device and method
GB201518076D0 (en) Methods and kits for determining deacylase activity
GB201912489D0 (en) Mass analysis apparatuses and methods
GB201814040D0 (en) Testing and therapy
EP4028055A4 (en) Methods and compositions for assessing and predicting therapeutic response
ES2493693A1 (en) Method for the prediction or prognosis of the response of a human subject suffering from cancer to treatment with an antagonist of the nk1 receptor
GB201801132D0 (en) Service platform and jaw crushing assembly including same